204 related articles for article (PubMed ID: 23965809)
1. Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.
Morton D; Sistare FD; Nambiar PR; Turner OC; Radi Z; Bower N
Toxicol Pathol; 2014 Jul; 42(5):799-806. PubMed ID: 23965809
[TBL] [Abstract][Full Text] [Related]
2. International Conference on Harmonisation; proposed change to rodent carcinogenicity testing of pharmaceuticals; request for comments. Notice; request for comments.
Food and Drug Administration, HHS
Fed Regist; 2013 Mar; 78(52):16681-4. PubMed ID: 23530289
[TBL] [Abstract][Full Text] [Related]
3. An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.
Storer RD; Sistare FD; Reddy MV; DeGeorge JJ
Toxicol Pathol; 2010 Jan; 38(1):51-61. PubMed ID: 19893055
[TBL] [Abstract][Full Text] [Related]
4. Regulatory Forum.
Peden WM
Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
[TBL] [Abstract][Full Text] [Related]
5. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
6. The in vivo rodent test systems for assessment of carcinogenic potential.
van der Laan JW; Spindler P
Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
[TBL] [Abstract][Full Text] [Related]
7. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS.
Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370
[TBL] [Abstract][Full Text] [Related]
8. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
[TBL] [Abstract][Full Text] [Related]
9. Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.
Downes N; Foster J
Toxicol Pathol; 2015 Dec; 43(8):1064-73. PubMed ID: 26296629
[TBL] [Abstract][Full Text] [Related]
10. The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals.
Nambiar PR; Morton D
Toxicol Pathol; 2013; 41(8):1058-67. PubMed ID: 23423820
[TBL] [Abstract][Full Text] [Related]
11. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
Contrera JF; DeGeorge JJ
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
[TBL] [Abstract][Full Text] [Related]
12. Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.
Urano K; Tamaoki N; Nomura T
Vet Pathol; 2012 Jan; 49(1):16-23. PubMed ID: 22146850
[TBL] [Abstract][Full Text] [Related]
13. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals--scientific perspective.
Storer RD
Toxicol Lett; 2000 Mar; 112-113():557-66. PubMed ID: 10720780
[TBL] [Abstract][Full Text] [Related]
14. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status.
Box RJ; Spielmann H
Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470
[TBL] [Abstract][Full Text] [Related]
15. Regulatory Forum Opinion Piece*: Transgenic/Alternative Carcinogenicity Assays: A Retrospective Review of Studies Submitted to CDER/FDA 1997-2014.
Jacobs AC; Brown PC
Toxicol Pathol; 2015 Jul; 43(5):605-10. PubMed ID: 25630682
[TBL] [Abstract][Full Text] [Related]
16. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals.
Contrera JF; Jacobs AC; DeGeorge JJ
Regul Toxicol Pharmacol; 1997 Apr; 25(2):130-45. PubMed ID: 9185889
[TBL] [Abstract][Full Text] [Related]
17. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the carcinogenic potential of pharmaceuticals. Opportunities arising from the International Conference on Harmonisation.
Monro AM; MacDonald JS
Drug Saf; 1998 May; 18(5):309-19. PubMed ID: 9589843
[TBL] [Abstract][Full Text] [Related]
19. Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?
Abraham J; Reed T
Soc Sci Med; 2003 Jul; 57(2):195-204. PubMed ID: 12765701
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
Friedrich A; Olejniczak K
Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
